

# Amy Kunchok

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6409091/publications.pdf>

Version: 2024-02-01

37  
papers

4,050  
citations

257450

24  
h-index

377865

34  
g-index

37  
all docs

37  
docs citations

37  
times ranked

2908  
citing authors

#	ARTICLE	IF	CITATIONS
1	Brain Abnormalities in Neuromyelitis Optica. Archives of Neurology, 2006, 63, 390.	4.5	637
2	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOMentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet, The, 2019, 394, 1352-1363.	13.7	433
3	Glial fibrillary acidic protein immunoglobulin <scp>G</scp> as biomarker of autoimmune astrocytopathy: Analysis of 102 patients. Annals of Neurology, 2017, 81, 298-309.	5.3	366
4	Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. American Journal of Ophthalmology, 2018, 195, 8-15.	3.3	295
5	Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgGâ€“Associated Disorders. JAMA Neurology, 2018, 75, 1355.	9.0	286
6	Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. JAMA Neurology, 2019, 76, 301.	9.0	243
7	Glutamic Acid Decarboxylase Autoimmunity With Brainstem, Extrapyrarnidal, and Spinal Cord Dysfunction. Mayo Clinic Proceedings, 2006, 81, 1207-1214.	3.0	212
8	Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology, 2013, 81, 1197-1204.	1.1	206
9	A multicenter comparison of MOG-IgG cell-based assays. Neurology, 2019, 92, e1250-e1255.	1.1	135
10	Area postrema syndrome. Neurology, 2018, 91, e1642-e1651.	1.1	129
11	Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. JAMA Neurology, 2021, 78, 741.	9.0	124
12	Clinical utility of testing AQP4-IgG in CSF. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e231.	6.0	113
13	GABA <sub>B</sub> receptor autoantibody frequency in service serologic evaluation. Neurology, 2013, 81, 882-887.	1.1	111
14	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Frontiers in Neurology, 0, 13, .	2.4	84
15	Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. Neurology, 2021, 97, e1097-e1109.	1.1	77
16	Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Multiple Sclerosis Journal, 2021, 27, 303-308.	3.0	64
17	Coexistence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies in Adult and Pediatric Patients. JAMA Neurology, 2020, 77, 257.	9.0	56
18	Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 384-390.	1.9	55

#	ARTICLE	IF	CITATIONS
19	Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin Gâ€ Associated Disorder. JAMA Neurology, 2020, 77, 1575.	9.0	52
20	Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies. American Journal of Ophthalmology, 2020, 220, 110-114.	3.3	48
21	CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1071-1080.	2.3	45
22	GABA <sub>A</sub> receptor autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e552.	6.0	42
23	Neuromyelitis Optica: A New Perspective. Seminars in Neurology, 2008, 28, 095-104.	1.4	31
24	Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgGâ€ associated disorders (MOGAD)?. Neurology, 2020, 94, 85-88.	1.1	30
25	MOG-IgG1 and co-existence of neuronal autoantibodies. Multiple Sclerosis Journal, 2021, 27, 1175-1186.	3.0	29
26	Autoimmune/Paraneoplastic Encephalitis Antibody Biomarkers: Frequency, Age, and Sex Associations. Mayo Clinic Proceedings, 2022, 97, 547-559.	3.0	29
27	Autoantibody-Associated Central Nervous System Neurologic Disorders. Seminars in Neurology, 2016, 36, 382-396.	1.4	27
28	CRMP5-IgGâ€ Associated Paraneoplastic Myelopathy With PD-L1 Inhibitor Therapy. JAMA Neurology, 2020, 77, 255.	9.0	26
29	Fatal reversible cerebral vasoconstriction syndrome. Journal of the Neurological Sciences, 2018, 385, 146-150.	0.6	14
30	Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgGâ€ Associated Disorders. JAMA Neurology, 2020, 77, 1572.	9.0	14
31	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Multiple Sclerosis Journal, 2021, 27, 2052-2061.	3.0	11
32	Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110526.	1.0	11
33	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Multiple Sclerosis Journal, 2021, 27, 695-705.	3.0	7
34	Selective total conjugate horizontal gaze paralysis due to bilateral abducens nucleus lesions. Journal of Neurology, 2016, 263, 2538-2539.	3.6	5
35	Paraneoplastic cerebellar ataxia with central hypoventilation. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e305.	6.0	3
36	Airplane stroke syndrome â€ Seven more flight-induced cases. Journal of Clinical Neuroscience, 2017, 39, 221-222.	1.5	0

#	ARTICLE	IF	CITATIONS
37	Encephalopathy after chocolate consumption. Medical Journal of Australia, 2018, 208, 110-110.	1.7	0